Welcome to our dedicated page for Nautilus Biotechnology news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology stock.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) is a development stage life sciences company developing a single-molecule proteome analysis platform, and the news surrounding NAUT often centers on progress toward validating and deploying this technology. The company’s communications highlight its Iterative Mapping method, tau proteoforms assay, and collaborations with leading research institutions as key themes in its news flow.
Readers following Nautilus news can expect updates on platform development milestones, such as the successful installation and testing of the first external field evaluation unit at the Buck Institute for Research on Aging. News has described how researchers at the Buck Institute generated highly reproducible tau proteoform data from neurodegenerative disease samples and used the Nautilus Proteome Analysis Platform to explore region-specific proteoform patterns associated with disease progression.
NAUT news also covers agreements and collaborations, including an agreement with the Allen Institute focused on investigating the connection between tau protein and neurodegenerative conditions such as Alzheimer’s disease. These announcements often discuss efforts to identify novel tau proteoforms, quantify their prevalence, and characterize phosphorylation patterns that may help explain disease course.
Financial results and corporate updates are another important category of Nautilus news. The company regularly issues quarterly earnings press releases describing operating expenses, net loss, cash, cash equivalents, and investments, along with commentary on development progress and plans for its platform and Early Access Program. Investors can also find notices about upcoming earnings calls, participation in healthcare and investor conferences, and regulatory filings reported via Form 8-K.
In addition, Nautilus has announced an Early Access Program for its proteomics platform, starting with a tau proteoforms assay, which is a recurring topic in its news. These articles explain how selected researchers gain access to the Iterative Mapping method, receive support for data interpretation and analysis, and participate in custom assay development partnerships. For anyone tracking NAUT, this news page provides a centralized view of technology, collaboration, commercialization, and financial developments related to the company’s single-molecule proteomics efforts.
Nautilus Biotechnology (NASDAQ: NAUT) has announced a strategic partnership with Abcam to enhance its reagent development capabilities. This collaboration aims to accelerate R&D by utilizing Abcam's advanced monoclonal antibody technologies. The focus will be on developing affinity binding reagents for Nautilus' proteomic analysis system, followed by large-scale manufacturing and commercialization. This partnership is seen as a significant step toward improving drug and diagnostic tool development, enhancing the overall efficacy of Nautilus’ protein analysis platform.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported its third-quarter financial results for 2021, highlighting significant business developments and financial metrics. The company initiated a strategic partnership with Abcam to enhance protein detection and signed two new research collaborations with a global pharmaceutical company and UT MD Anderson Cancer Center. Financially, Nautilus recorded an operating expense of $14.6 million, a 262% increase from the previous year, and a net loss of $14.5 million. However, cash reserves stood strong at $374 million as of September 30, 2021.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will report its financial results for Q3 2021 on November 2, 2021. Prior to the market open, the company will hold a webcast at 5:30 a.m. PT / 8:30 a.m. ET to discuss its results and business developments. Nautilus is focused on a single-molecule protein analysis platform aimed at revolutionizing proteomics and enhancing human health and medicine.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will participate virtually at the Morgan Stanley Global Healthcare Conference on September 15, 2021, at 1:15 p.m. ET. The event will feature a presentation detailing Nautilus' innovative single-molecule protein analysis platform that quantifies the human proteome. Attendees can access a live and archived webcast through Nautilus' website. The company aims to enhance basic science research and improve therapeutic development through its advanced proteomics technology.
Nautilus Biotechnology reported its second quarter 2021 financial results, revealing significant developments since becoming publicly traded on June 10, 2021, with gross proceeds of approximately $345.5 million. The company's operating expenses surged by 215% to $10.7 million, compared to $3.4 million in Q2 2020, primarily due to increased headcount and public company costs. The net loss for the quarter was $10.7 million, up from $3.4 million year-over-year. Nautilus aims for platform commercialization by late 2023 and bolstered its team with key appointments.
Nautilus Biotechnology has appointed Karl Voss, Ph.D., as the new Vice President of Life Sciences Research and Development. With over 20 years of experience, Dr. Voss previously worked at Pacific Biosciences, where he significantly contributed to the advancement of single-molecule DNA sequencing. His expertise is expected to enhance Nautilus’ mission to transform understanding in human biology through their innovative protein analysis platform, which aims to quantify over 95% of the proteome. This appointment follows Nautilus' recent public trading debut.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced plans to report its financial results for Q2 of fiscal year 2021 on August 10, 2021, before the market opens. A webcast conference call will follow at 5:00 a.m. PT / 8:00 a.m. ET to discuss the results, business developments, and future outlook. Nautilus focuses on pioneering a single-molecule protein analysis platform to advance proteomics, aiming to enhance accessibility to proteomic data and contribute to advancements in human health and medicine.
Nautilus Biotechnology announced the appointment of Dr. Emma Lundberg to its Scientific Advisory Board, effective immediately. Lundberg is a pioneer in spatial proteomics, bringing extensive expertise in human cell biology and artificial intelligence. Her role supports Nautilus's mission to develop a single-molecule protein analysis platform aimed at quantifying the proteome. This strategic addition follows Nautilus's recent public debut, backed by $345 million raised from its business combination with Arya Sciences Acquisition Corp III, aiming to fundamentally enhance biomedical research and diagnostics.
Nautilus Biotechnology completed its business combination with Arya Sciences Acquisition Corp III on June 9, 2021, and will trade under ticker symbol NAUT on the Nasdaq beginning June 10, 2021. The deal generated $345 million in gross proceeds, comprising $145 million from Arya III's trust account and $200 million in PIPE financing. The company aims to revolutionize proteomics with its technology, which could identify over 95% of the proteome using innovative approaches. Led by CEO Sujal Patel and Chief Scientist Parag Mallick, Nautilus is focused on advancing drug development and biomedical research.